{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:57:24Z","timestamp":1789930644492,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:00:00Z","timestamp":1496793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:00:00Z","timestamp":1496793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1038\/ja.2017.56","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T06:20:44Z","timestamp":1496816444000},"page":"907-910","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus"],"prefix":"10.1038","volume":"70","author":[{"given":"Fumiaki","family":"Tabuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Tatsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoji","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Sekimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,7]]},"reference":[{"key":"BFja201756_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1128\/CMR.00042-09","volume":"23","author":"BP Howden","year":"2010","unstructured":"Howden, B. P., Davies, J. K., Johnson, P. D., Stinear, T. P. & Grayson, M. L. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23, 99\u2013139 (2010).","journal-title":"Clin. Microbiol. Rev."},{"key":"BFja201756_CR2","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1056\/NEJMoa025025","volume":"348","author":"S Chang","year":"2003","unstructured":"Chang, S. et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348, 1342\u20131347 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFja201756_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(13)61219-2","volume":"382","author":"J Melo-Cristino","year":"2013","unstructured":"Melo-Cristino, J., Resina, C., Manuel, V., Lito, L. & Ramirez, M. First case of infection with vancomycin-resistant Staphylococcus aureus in Europe. Lancet 382, 205 (2013).","journal-title":"Lancet"},{"key":"BFja201756_CR4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/jac\/dki486","volume":"57","author":"J Robert","year":"2006","unstructured":"Robert, J., Bismuth, R. & Jarlier, V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J. Antimicrob. Chemother. 57, 506\u2013510 (2006).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFja201756_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/jac\/dkg104","volume":"51","author":"P Wilson","year":"2003","unstructured":"Wilson, P. et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 51, 186\u2013188 (2003).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFja201756_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1749-6632.2012.06819.x","volume":"1277","author":"AS Bayer","year":"2013","unstructured":"Bayer, A. S., Schneider, T. & Sahl, H. G. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann. N. Y. Acad. Sci. 1277, 139\u2013158 (2013).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"BFja201756_CR7","doi-asserted-by":"publisher","first-page":"17092","DOI":"10.1038\/srep17092","volume":"5","author":"K Ishii","year":"2015","unstructured":"Ishii, K. et al. Phenotypic and genomic comparisons of highly vancomycin-resistant Staphylococcus aureus strains developed from multiple clinical MRSA strains by in vitro mutagenesis. Sci. Rep. 5, 17092 (2015).","journal-title":"Sci. Rep."},{"key":"BFja201756_CR8","doi-asserted-by":"crossref","unstructured":"Tabuchi, F. et al. Synergistic effects of vancomycin and beta-lactams against vancomycin highly resistant Staphylococcus aureus. J. Antibiot. (Tokyo) (2017).","DOI":"10.1038\/ja.2017.7"},{"key":"BFja201756_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2174\/1568026616666160713143017","volume":"17","author":"J Brunetti","year":"2016","unstructured":"Brunetti, J., Falciani, C., Bracci, L. & Pini, A. Models of in-vivo bacterial infections for the development of antimicrobial peptide-based drugs. Curr. Top. Med. Chem. 17, 613\u2013619 (2016).","journal-title":"Curr. Top. Med. Chem."},{"key":"BFja201756_CR10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1099\/jmm.0.074245-0","volume":"63","author":"J Krezdorn","year":"2014","unstructured":"Krezdorn, J., Adams, S. & Coote, P. J. A Galleria mellonella infection model reveals double and triple antibiotic combination therapies with enhanced efficacy versus a multidrug-resistant strain of Pseudomonas aeruginosa. J. Med. Microbiol. 63, 945\u2013955 (2014).","journal-title":"J. Med. Microbiol."},{"key":"BFja201756_CR11","doi-asserted-by":"publisher","first-page":"6390","DOI":"10.1016\/j.bmc.2016.11.008","volume":"24","author":"M Zhao","year":"2016","unstructured":"Zhao, M., Lepak, A. J. & Andes, D. R. Animal models in the pharmacokinetic\/pharmacodynamic evaluation of antimicrobial agents. Bioorg. Med. Chem. 24, 6390\u20136400 (2016).","journal-title":"Bioorg. Med. Chem."},{"key":"BFja201756_CR12","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1099\/jmm.0.071837-0","volume":"63","author":"MO Poulsen","year":"2014","unstructured":"Poulsen, M. O. et al. Combination therapy with thioridazine and dicloxacillin combats meticillin-resistant Staphylococcus aureus infection in Caenorhabditis elegans. J. Med. Microbiol. 63, 1174\u20131180 (2014).","journal-title":"J. Med. Microbiol."},{"key":"BFja201756_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1006\/mpat.2002.0494","volume":"32","author":"C Kaito","year":"2002","unstructured":"Kaito, C., Akimitsu, N., Watanabe, H. & Sekimizu, K. Silkworm larvae as an animal model of bacterial infection pathogenic to humans. Microb. Pathog. 32, 183\u2013190 (2002).","journal-title":"Microb. Pathog."},{"key":"BFja201756_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2672.2011.05186.x","volume":"112","author":"Y Matsumoto","year":"2012","unstructured":"Matsumoto, Y. et al. Quantitative evaluation of cryptococcal pathogenesis and antifungal drugs using a silkworm infection model with Cryptococcus neoformans. J. Appl. Microbiol. 112, 138\u2013146 (2012).","journal-title":"J. Appl. Microbiol."},{"key":"BFja201756_CR15","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1128\/AAC.48.3.774-779.2004","volume":"48","author":"H Hamamoto","year":"2004","unstructured":"Hamamoto, H. et al. Quantitative evaluation of the therapeutic effects of antibiotics using silkworms infected with human pathogenic microorganisms. Antimicrob. Agents Chemother. 48, 774\u2013779 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja201756_CR16","first-page":"349","volume":"4","author":"T Fujiyuki","year":"2010","unstructured":"Fujiyuki, T., Imamura, K., Hamamoto, H. & Sekimizu, K. Evaluation of therapeutic effects and pharmacokinetics of antibacterial chromogenic agents in a silkworm model of Staphylococcus aureus infection. Drug Discov. Ther. 4, 349\u2013354 (2010).","journal-title":"Drug Discov. Ther."},{"key":"BFja201756_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5582\/ddt.2016.01025","volume":"10","author":"K Usui","year":"2016","unstructured":"Usui, K. et al. Acute oral toxicity test of chemical compounds in silkworms. Drug Discov. Ther. 10, 57\u201361 (2016).","journal-title":"Drug Discov. Ther."},{"key":"BFja201756_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nchembio.1710","volume":"11","author":"H Hamamoto","year":"2015","unstructured":"Hamamoto, H. et al. Lysocin E is a new antibiotic that targets menaquinone in the bacterial membrane. Nat. Chem. Biol. 11, 127\u2013133 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"BFja201756_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.5582\/ddt.2014.01050","volume":"8","author":"R Uchida","year":"2014","unstructured":"Uchida, R. et al. In vitro and in vivo anti-MRSA activities of nosokomycins. Drug Discov. Ther. 8, 249\u2013254 (2014).","journal-title":"Drug Discov. Ther."},{"key":"BFja201756_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/ja.2010.9","volume":"63","author":"R Uchida","year":"2010","unstructured":"Uchida, R. et al. Nosokomycins, new antibiotics discovered in an in vivo-mimic infection model using silkworm larvae. I: fermentation, isolation and biological properties. J. Antibiot. (Tokyo) 63, 151\u2013155 (2010).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja201756_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1248\/cpb.c15-00743","volume":"64","author":"H Tomoda","year":"2016","unstructured":"Tomoda, H. New approaches to drug discovery for combating MRSA. Chem. Pharm. Bull. (Tokyo) 64, 104\u2013111 (2016).","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"BFja201756_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/ja.2010.10","volume":"63","author":"R Uchida","year":"2010","unstructured":"Uchida, R., Iwatsuki, M., Kim, Y. P., Omura, S. & Tomoda, H. Nosokomycins, new antibiotics discovered in an in vivo-mimic infection model using silkworm larvae. II: structure elucidation. J. Antibiot. (Tokyo) 63, 157\u2013163 (2010).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja201756_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/ja.2016.106","volume":"70","author":"I Nakamura","year":"2017","unstructured":"Nakamura, I. et al. Discovery of a new antifungal agent ASP2397 using a silkworm model of Aspergillus fumigatus infection. J. Antibiot. (Tokyo) 70, 41\u201344 (2017).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja201756_CR24","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1128\/jb.170.9.4365-4372.1988","volume":"170","author":"HL Peng","year":"1988","unstructured":"Peng, H. L., Novick, R. P., Kreiswirth, B., Kornblum, J. & Schlievert, P. Cloning, characterization, and sequencing of an accessory gene regulator (agr in Staphylococcus aureus. J. Bacteriol. 170, 4365\u20134372 (1988).","journal-title":"J. Bacteriol."},{"key":"BFja201756_CR25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/35021219","volume":"406","author":"C Walsh","year":"2000","unstructured":"Walsh, C. Molecular mechanisms that confer antibacterial drug resistance. Nature 406, 775\u2013781 (2000).","journal-title":"Nature"},{"key":"BFja201756_CR26","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/febs.12108","volume":"280","author":"GA Prosser","year":"2013","unstructured":"Prosser, G. A. & de Carvalho, L. P. Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by the antibiotic D-cycloserine. FEBS J. 280, 1150\u20131166 (2013).","journal-title":"FEBS J."},{"key":"BFja201756_CR27","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1128\/AAC.00799-13","volume":"57","author":"O Gasch","year":"2013","unstructured":"Gasch, O. et al. Daptomycin in vitro activity against methicillin-resistant Staphylococcus aureus is enhanced by D-cycloserine in a mechanism associated with a decrease in cell surface charge. Antimicrob. Agents Chemother. 57, 4537\u20134539 (2013).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ja201756.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ja201756","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ja.2017.56","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/ja201756.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T02:18:16Z","timestamp":1641003496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ja201756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,7]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["BFja201756"],"URL":"https:\/\/doi.org\/10.1038\/ja.2017.56","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,7]]},"assertion":[{"value":"13 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KS has an advisory role at Genome Pharmaceuticals Institute Co., Ltd (Tokyo, Japan). All remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}